Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00259038
Recruitment Status : Completed
First Posted : November 29, 2005
Last Update Posted : November 8, 2016
Information provided by (Responsible Party):
Daiichi Sankyo, Inc.

Brief Summary:
The study will evaluate the safety and efficacy of intravenous infusion of carperitide using pressure measurements inside the heart and great vessels and measuring carperitide concentration in the blood.

Condition or disease Intervention/treatment Phase
Heart Failure, Congestive Heart Decompensation Left Ventricular Failure Myocardiopathies Systolic or Diastolic Left Ventricular Dysfunction Drug: Carperitide Drug: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 162 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II, Dose Escalation Evaluation of the Pharmacokinetic and Hemodynamic Effects of Carperitide in Subjects With Congestive Heart Failure
Study Start Date : January 2004
Actual Primary Completion Date : February 2006
Actual Study Completion Date : February 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Experimental Drug Drug: Carperitide
Other Name: human recombinant atrial natriuretic peptide
Placebo Comparator: Placebo Drug: Placebo

Primary Outcome Measures :
  1. Change from baseline in pulmonary capillary wedge pressure (PCWP) [ Time Frame: at 3 hours following initiation of study drug infusion ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Is hospitalized with congestive heart failure (CHF)
  • Has a Swan-Ganz catheter inserted for CHF management and has pulmonary capillary wedge pressure 18 mmHg or higher

Exclusion Criteria:

  • Has had a heart transplant
  • Requires mechanical ventilation or mechanical circulatory support

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00259038

  Show 34 Study Locations
Sponsors and Collaborators
Daiichi Sankyo, Inc.
Study Director: Biljana Pavlovic-Surjancev, MD, PhD Astellas Pharma US, Inc.

Responsible Party: Daiichi Sankyo, Inc. Identifier: NCT00259038     History of Changes
Other Study ID Numbers: 03-0-162
First Posted: November 29, 2005    Key Record Dates
Last Update Posted: November 8, 2016
Last Verified: November 2016

Keywords provided by Daiichi Sankyo, Inc.:
Atrial Natriuretic Peptide
Treatment efficacy
Heart failure, Congestive
Pulmonary Artery Catheterization

Additional relevant MeSH terms:
Heart Failure
Ventricular Dysfunction
Ventricular Dysfunction, Left
Heart Diseases
Cardiovascular Diseases